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体，在激活 PPARα 时存在结构选择性。本论文研究的化合物 S-油酰丙醇胺是
OEA 的结构类似物，具光学活性，体外分子实验结果表明 S-油酰丙醇胺和大多
数的 PPARα激动剂一样，能够通过激活 PPARα来抑制慢性炎症。 





方法  1、通过 大耐受量（MTD）实验和 λ-角叉菜胶致小鼠后足跖肿胀
实验分别考察 S-油酰丙醇胺的安全性及抗炎作用，抗炎作用设置高、中、低三




胃口服方式给予 SD 大鼠 S-油酰丙醇胺，检测不同时间点血浆中药物浓度，利
用 WinNolin 软件计算药代动力学参数；采用灌胃口服方式给予 SD 大鼠 S-油酰
丙醇胺，于不同时间点处死大鼠，取脑、心、肺、肝、脾、肾、小肠、脂肪、
肌肉等组织，检测组织中药物浓度，研究药物组织分布特征。 


















符合生物样品分析要求。3、S-油酰丙醇胺静脉注射半衰期 t1/2为（44.8 ± 8.3）





三个剂量组的动力学参数包括 t1/2分别为：（124.1 ± 21.9）min、（142.2 ± 23.2）




























































Peroxisome proliferator-activated receptor-alpha (PPARα) is a nuclear receptor 
which regulates expression of genes encoding proteins that involved in lipid 
metabolism, fatty acid oxidation, and glucose homeostasis. In addition, PPARα 
exerts anti-inflammatory effects both in vascular wall and the liver. PPARα 
activation interferes with early steps in atherosclerosis by reducing the adhesion of 
leukocyte to activated endothelial cells of the arterial vessel wall and inhibiting 
subsequent migration of trans-endothelial leukocyte. PPARα is activated by natural 
ligands and synthetic ligands. Oleoylethanolamide (OEA) is natural lipid which 
binds with high affinity to PPARα, severed as an endogenous agnoist of PPARα. 
(Z)-(S)-9-octadecenamide, N-(2-hydroxyethyl,1-methy), OPA, studied in this paper 
is an analog of OEA. Previous studies in vitro showed that OPA activated PPARα as 
other endogenous agnoists of PPARα and was supposed to limit chronic 
inflammation. 
Object Firstly, this study was to investigate the safety of OPA by the acute 
toxicity reaction followed by the studies of anti-inflammatory effect and the 
dose-effect relationship. It was aimed to develop a rapid and sensitive method for the 
determination and quantification of OPA in rat plasma and various tissues, and to 
assess the applicability of the assay to pharmacokinetic studies and tissue 
distribution. It was supposed to provide the experimental data for preclinical 
evaluation of OPA. 
Methods 1. We investigated the acute toxicity of OPA by the maximum tolerated 
dose (MTD) and evaluated the anti-edema effect of OPA in the carrageenan model in 
different doses. For comparison, the effects of OEA and fenofibrate were evaluated 
as well. 2. OPA was extracted by liquid-liquid extraction method with 
undecylenoylethanolamide as an internal standard. HPLC-MS/MS was equipped 
with an atmospheric pressure chemical ionization (APCI) source operating in 















(MRM). 3. The concentration of OPA in plasma was determined after administration 
of (i) a single intravenous dose (ii) three levels of intragastric doses in rats. The 
pharmacokinetics parameters were calculated by WinNolin software. For tissue 
distribution study, the concentrations in various tissues (brain, heart, lung, liver, 
spleen, small intestine, kidney, adipose tissue and muscle) were determined after 
administration of a single intragastric dose in 4 time points.  
Results 1. The oral half lethal dose (LD50) of OPA can not be calculated and the 
MTD was 2400 mg·kg-1; OPA was effective in preventing paw edema and its effect 
was dose-dependent. 2. The calibration curves of plasma samples and tissue 
homogenates were well linear (r ≥ 0.9990). Validation parameters such as accuracy, 
precision, recovery were found to be within the acceptance criteria of the assay 
validation guidelines. 3. The main pharmacokinetic parameters of OPA included t1/2: 
(44.8 ± 8.3) min and CL: (21.3 ± 3.1) L·min-1·kg-1 for intravenous injection. For oral 
administration the parameters were t1/2: (124.1 ± 21.9) min, (142.2 ± 23.2) min and 
(139.1 ± 31.0) min; CL/F: (303.5 ± 76.5) L·min-1·kg-1, (134.9 ± 17.4) L·min-1·kg-1 
and (132.7 ± 29.6) L·min-1·kg-1. Absolute bioavailability (F) was less than 20%. 
There was rapid and wide distribution in tissues especially in the small intestine, 
heart, adipose tissue and liver. 
Conclusion Oral administration of OPA was safe and low-poisonous for mouse. 
OPA was more effective than OEA and fenofibrate in preventing 
carrageenan-induced paw edema and its effect was dose-dependent. The 
quantification method of OPA was rapid, sensitive and suitable to investigate the 
pharmacokinetics and tissue distribution study. The pharmacokinetic results showed 
rapid absorption and elimination of OPA, but with a low level of bioavailability. The 
highest concentration was found in heart and liver. OPA was absorbed in small 
intestine and stored in adipose tissue. 
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第一章  前  言 
1.1  过氧化物酶体增殖物激活受体-α（PPARα）与动脉粥样硬化的
关系 
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图 1.2  常见的 PPARα天然配体-内源性大麻素受体配体化学结构式 
NAEs 的合成包括 N-酰基磷脂酰乙醇胺（NAPE）和一系列酶介物质，如 NAPE
水解化磷脂酶 D（NAPE-PLD）[20]；NAEs 的水解则由脂肪酸天门冬酰胺酶（FAAH）
催化完成[21]。 
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